A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis.

Registry ID

EUCTR2007-003745-32

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

University of Nottingham

Start date

2008-12-12

Completion date

2014-05-01

Last update

2026-08-16

Conditions

• Lymphangioleiomyomatosis

Summary

Does doxycycline prevent matrix metalloproteinase dependent tissue destruction in lymphangioleiomyomatosis (LAM) thus preserving lung function, exercise capacity and quality of life in LAM?

Locations

• , , UK

Related clinical trials

• Study of the Disease Process of Lymphangioleiomyomatosis
• Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
• TSC Biosample Repository and Natural History Database
• Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
• Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
• National Lymphangioleiomyomatosis Registry, France

View on source registry